Summary by Moomoo AI
Bristol-Myers Squibb Company (BMS) has responded to a comment letter from the U.S. Securities and Exchange Commission (SEC) regarding its tender offer statement for RayzeBio, Inc., initially filed on January 25, 2024. The SEC's letter, dated February 14, 2024, raised concerns about BMS's financing plans, the conditions of the offer, and the acceptance of tenders from shareholders in compliance with jurisdictional laws. BMS, along with its wholly owned subsidiary Rudolph Merger Sub Inc., has filed an amendment to the tender offer statement, addressing the SEC's comments and confirming their intention to comply with Commission rules and regulations. The amendment includes revised disclosures about the source and amount of funds, the conditions to the offer, and the acceptance of tenders from shareholders. BMS has assured the SEC that it will promptly inform RayzeBio stockholders of any developments that may affect the satisfaction of offer conditions.
